Abstract:In effort s to achieve minimal systemic toxicity and high tumor delivery efficiencies in cancer therapy, various nanomedicine formulations having stealth polymer coatings have been developed for minimizing immune cell uptake and off-target macrophage phagocyte system (MPS) organ accumulation. Despite an initial reduction in immune cell uptake, stealth nanoparticles still initiate an antibody immune response. This response acts on subsequent administrations in treatment regimens resulting in accelerated blood clearance of particles into MPS organs, particularly the liver, where they are retained for prolonged periods. Consequently, doses after the first administration in treatment regimens have diminished tumor accumulation and increased MPS toxicity. Here, we present a strategy reducing antibody responses to each dose in a treatment regimen by alternating between polyethylene-glycol and polymethyloxazoline polymers as the nanoparticle coating between administrations. In a weekly dosing regimen, we find that the first dose of particles having either coating display similar favorable pharmacokinetics and biodistributions, thus allowing the polymers to be used interchangeably. However, when maintaining the same coating in subsequent administrations, we find that particles are in circulation at the height of the antibody immune response resulting in 50-60% decreases of circulation half-lives and tumor accumulation along with 50% increases in liver accumulation. By alternating the polymers used in the nanoparticle coating between administrations, we find each dose maintains favorable in vivo behaviors at the height of the antibody immune response to the previous administration. Furthermore, our strategy increases the clearance of particles uptaken by macrophages and hepatocytes, resulting in marked decreases in hepatotoxicity. Statement of significance While nanoparticles with coatings consisting of stealth polymers can minimize immune cell uptake, they still initiate antibody immune responses leading to rapid blood clearance and MPS sequestration of subsequent administrations within a treatment regimen. We demonstrate that by alternating PEG and PMOZ polymer coatings between weekly administrations, the antibody immune response acting on each administration is minimal, and the favorable in vivo behaviors observed with the first administration is maintained in subsequent administrations. In this case, greater tumor accumulation is achieved while curtailing excessive MPS organ accumulation and toxicity throughout a nanomedicine treatment. We envision our strategy will benefit clinical trials where frequent administrations of therapeutics are required or in sequential deliveries of prognostic and therapeutic agents. (c) 2021 Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

A Phosphatase-Mimetic Nano-Stabilizer of Mast Cells for Long-Term Prevention of Allergic Disease.

Biodegradable Mesoporous Organosilica-Based Nanostabilizer Targeting Mast Cells for Long-Term Treatment of Allergic Diseases

Controlled adsorption of multiple bioactive proteins enables targeted mast cell nanotherapy

Cell-based phenotypic screening of mast cell degranulation unveils kinetic perturbations of agents targeting phosphorylation

The Inhibition Of Mast Cell Activation Of Radix Paeoniae Alba Extraction Identified By Tcrp Based And Conventional Cell Function Assay Systems

pH-responsive theranostic nanoplatform of ferrite and ceria co-engineered nanoparticles for anti-inflammatory

Mast cell stabilizers: from pathogenic roles to targeting therapies

A novel sustainable photo/chemical magnetic nanomaterial effectively mitigates the allergenicity of phospholipase A2

Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window

Alternating Stealth Polymer Coatings Between Administrations Minimizes Toxic and Antibody Immune Responses Towards Nanomedicine Treatment Regimens.

Multifunctional chitosan-coated poly(lactic-co-glycolic acid) nanoparticles for spatiotemporally controlled codelivery of ceramide and C-phycocyanin to treat atopic dermatitis

Inhibitory effect of phellodendrine on C48/80-induced allergic reaction in vitro and in vivo

Biomimetic Nanozymes Suppressed Ferroptosis to Ameliorate Doxorubicin-Induced Cardiotoxicity via Synergetic Effect of Antioxidant Stress and GPX4 Restoration

Berberine-Loaded Biomimetic Nanoparticles Attenuate Inflammation of Experimental Allergic Asthma Via Enhancing IL-12 Expression.

A drug-free nanozyme for mitigating oxidative stress and inflammatory bowel disease

Effect of Small-Molecule Natural Compounds on Pathologic Mast Cell/Basophil Activation in Allergic Diseases

Anti-asthmatic effect of nanoliposomal ceramides in a mouse model

Tackling Severe Neutrophilic Inflammation in Airway Disorders with Functionalized Nanosheets.

Preventive and Therapeutic Effects of Lactiplantibacillus plantarum HD02 and MD159 through Mast Cell Degranulation Inhibition in Mouse Models of Atopic Dermatitis

hCeO2@ Cu5.4O nanoparticle alleviates inflammatory responses by regulating the CTSB–NLRP3 signaling pathway

Bis-5HT Modified Paris Saponin II Nanoparticles Treat Neutrophil Infiltrating Allergic Rhinitis by Regulating the Alanine Metabolism Pathway